Gilead Sciences Inc (GILD)

$108.50 +0.50 (0.46%)
Market Cap 134.97B
Revenue (ttm) 28.75B
Net Income (ttm) 480.00M
EPS (ttm) N/A
PE Ratio 14.02
Forward PE 13.65
Profit Margin 1.67%
Debt to Equity Ratio 1.31
Volume 23,268,102
Avg Vol 9,139,328
Day's Range N/A - N/A
Shares Out 1.24B
Stochastic %K 21%
Beta 0.29
Analysts Strong Sell
Price Target $116.88

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis....

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 574 3000
Fax: 650 578 9264
Address:
333 Lakeside Drive, Foster City, United States
DonCorleone77
DonCorleone77 Jun. 21 at 2:34 PM
$GILD Information regarding analyst reports/notes on GILD issued Wednesday (6/18) and yesterday by: Needham: https://x.com/CorleoneDon77/status/1936428576821190993 RBC Capital Markets: https://x.com/CorleoneDon77/status/1936430173106184216 Mizuho: https://x.com/CorleoneDon77/status/1936431028001759519
0 · Reply
BioRich
BioRich Jun. 21 at 1:03 AM
$CLSD Feeling very fortunate to get in on this gem before it goes on a triple digit run. Locked and loaded on this low float. Hope you are too! Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital $XBI $JNJ $PFE $GILD
1 · Reply
MidnightMadness
MidnightMadness Jun. 20 at 8:23 PM
$GILD Going to add some shares. This was likely held back with a big options expiration day today. This has a good news story and momentum to carry toward 135 range. They are leaders in the HIV market and new HIV injection secures the leadership for many years to come. This allows them to springboard/mature the other franchises.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 20 at 7:08 PM
$ACB $ADBE $CCL $CRM $GILD As an FYI, I will be posting information over the weekend from recent analyst reports regarding the stocks listed below. If any of those companies are of interest to you, please feel free to check back for the information that will be posted. 1) ACB 2) ADBE 3) CCL 4) CRM 5) GILD 6) HD 7) IBM 8) MU 9) NKE 10) QBTS 11) RH 12) SNDX 13) TSLA I also hope everyone has a great weekend. -DC77
1 · Reply
tick_range_31
tick_range_31 Jun. 20 at 5:12 PM
$GILD
0 · Reply
BioRich
BioRich Jun. 20 at 4:22 PM
$PRTA Happily doubled my position here. Lucky to load up on this gem. Foresee exciting short-term and long-term potential here. Recent pull back allows for tremendous investment here. Lots of shots on goal and appears to be a winner. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $PFE $GILD $LLY
0 · Reply
WickMaster
WickMaster Jun. 20 at 3:58 PM
$GILD
0 · Reply
MomentumWins
MomentumWins Jun. 20 at 3:51 PM
$GILD positive media coverage just now
0 · Reply
B5BusinessMan
B5BusinessMan Jun. 20 at 3:50 PM
$GILD sold it with -4 loss, sad day for me... 🫠
0 · Reply
ripztrip
ripztrip Jun. 20 at 3:32 PM
$CAPR shorts here are SO devious!!!! jeez. TRYING to do whatever they can to keep it BELOW 10?? this going to be approved shortly. marked. KNOW what you own!!!! This way a hit and run today with a lot of people with stop losses pushed out for no reason..... $SRPT $PFE $ABBV $GILD
0 · Reply
Latest News on GILD
AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention

Jun 18, 2025, 5:38 PM EDT - 3 days ago

AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Jun 18, 2025, 2:49 PM EDT - 3 days ago

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

Jun 18, 2025, 2:30 PM EDT - 3 days ago

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

US FDA approves Gilead's twice-yearly injection for HIV prevention

Jun 18, 2025, 2:24 PM EDT - 3 days ago

US FDA approves Gilead's twice-yearly injection for HIV prevention

Should You Buy Gilead Stock At $110?

Jun 18, 2025, 9:15 AM EDT - 3 days ago

Should You Buy Gilead Stock At $110?

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 17, 2025, 10:00 AM EDT - 4 days ago

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gilead Sciences, Inc. (GILD) and Encourages Stockholders to Learn More About the Investigation

Jun 16, 2025, 10:00 AM EDT - 5 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gilead Sciences, Inc. (GILD) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities Investigation

Jun 15, 2025, 10:00 AM EDT - 6 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities Investigation

Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline

Jun 15, 2025, 8:31 AM EDT - 6 days ago

Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Investors to Reach Out

Jun 13, 2025, 10:00 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out

Jun 12, 2025, 12:00 PM EDT - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 10, 2025, 1:15 PM EDT - 11 days ago

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination

Jun 10, 2025, 10:02 AM EDT - 11 days ago

US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination

Final Trade: NVO, CELH, LION, GILD

Jun 9, 2025, 6:23 PM EDT - 12 days ago

Final Trade: NVO, CELH, LION, GILD

CELH NVO LION

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

Jun 5, 2025, 1:09 PM EDT - 16 days ago

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)

Jun 4, 2025, 3:19 PM EDT - 17 days ago

Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Jun 3, 2025, 3:34 PM EDT - 18 days ago

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

AZN PFE AMGN BMY BNTX MRK

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Jun 1, 2025, 8:03 AM EDT - 20 days ago

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Jun 1, 2025, 8:00 AM EDT - 20 days ago

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Potentially Earn 12%-15% Income: Monthly Options Series (June 2025)

May 31, 2025, 8:30 AM EDT - 21 days ago

Potentially Earn 12%-15% Income: Monthly Options Series (June 2025)

AMAT APH AVGO BK BMI CTAS GL

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

May 31, 2025, 8:13 AM EDT - 21 days ago

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

MRK

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

May 31, 2025, 8:00 AM EDT - 21 days ago

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Focus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty

May 30, 2025, 6:06 AM EDT - 22 days ago

Focus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty

Gilead Sciences, Inc. (GILD) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

May 29, 2025, 5:50 PM EDT - 23 days ago

Gilead Sciences, Inc. (GILD) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 24 days ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR IBB ILMN NVS SDGR

Gilead Sciences' Best Days May Be Ahead - Here's Why

May 26, 2025, 10:32 AM EDT - 26 days ago

Gilead Sciences' Best Days May Be Ahead - Here's Why

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

May 23, 2025, 8:30 AM EDT - 4 weeks ago

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Final Trade: WMT, GILD, DECK, ROST

May 22, 2025, 6:27 PM EDT - 4 weeks ago

Final Trade: WMT, GILD, DECK, ROST

WMT DECK ROST

Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)

May 21, 2025, 3:28 PM EDT - 4 weeks ago

Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

May 15, 2025, 4:15 PM EDT - 5 weeks ago

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript

May 13, 2025, 7:32 PM EDT - 5 weeks ago

Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

May 12, 2025, 12:36 PM EDT - 5 weeks ago

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

ABBV AMGN AZN GSK JNJ LLY MRK

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

May 12, 2025, 12:30 PM EDT - 5 weeks ago

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

ABBV AMGN BIIB BMY JNJ LLY MRK

Pressure is still on the pharma sector, says Mizuho's Jared Holz

May 8, 2025, 7:23 PM EDT - 6 weeks ago

Pressure is still on the pharma sector, says Mizuho's Jared Holz

ABBV AMGN BMY JNJ LLY MRK NVO

Gilead announces $11 billion in new investments in US

May 7, 2025, 2:52 PM EDT - 6 weeks ago

Gilead announces $11 billion in new investments in US

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

May 7, 2025, 2:30 AM EDT - 6 weeks ago

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

May 7, 2025, 2:15 AM EDT - 6 weeks ago

Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Gilead Sciences to Present at Upcoming Investor Conferences

Apr 29, 2025, 4:05 PM EDT - 7 weeks ago

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Apr 29, 2025, 1:51 PM EDT - 7 weeks ago

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions

Apr 29, 2025, 1:45 PM EDT - 7 weeks ago

Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Apr 29, 2025, 8:30 AM EDT - 7 weeks ago

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks

Apr 27, 2025, 7:00 AM EDT - 7 weeks ago

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks

We're in a pharma stock pickers market, says Kessef's Len Yaffe

Apr 25, 2025, 6:06 PM EDT - 2 months ago

We're in a pharma stock pickers market, says Kessef's Len Yaffe

ABBV BMY JNJ LLY MRK PFE REGN

DonCorleone77
DonCorleone77 Jun. 21 at 2:34 PM
$GILD Information regarding analyst reports/notes on GILD issued Wednesday (6/18) and yesterday by: Needham: https://x.com/CorleoneDon77/status/1936428576821190993 RBC Capital Markets: https://x.com/CorleoneDon77/status/1936430173106184216 Mizuho: https://x.com/CorleoneDon77/status/1936431028001759519
0 · Reply
BioRich
BioRich Jun. 21 at 1:03 AM
$CLSD Feeling very fortunate to get in on this gem before it goes on a triple digit run. Locked and loaded on this low float. Hope you are too! Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital $XBI $JNJ $PFE $GILD
1 · Reply
MidnightMadness
MidnightMadness Jun. 20 at 8:23 PM
$GILD Going to add some shares. This was likely held back with a big options expiration day today. This has a good news story and momentum to carry toward 135 range. They are leaders in the HIV market and new HIV injection secures the leadership for many years to come. This allows them to springboard/mature the other franchises.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 20 at 7:08 PM
$ACB $ADBE $CCL $CRM $GILD As an FYI, I will be posting information over the weekend from recent analyst reports regarding the stocks listed below. If any of those companies are of interest to you, please feel free to check back for the information that will be posted. 1) ACB 2) ADBE 3) CCL 4) CRM 5) GILD 6) HD 7) IBM 8) MU 9) NKE 10) QBTS 11) RH 12) SNDX 13) TSLA I also hope everyone has a great weekend. -DC77
1 · Reply
tick_range_31
tick_range_31 Jun. 20 at 5:12 PM
$GILD
0 · Reply
BioRich
BioRich Jun. 20 at 4:22 PM
$PRTA Happily doubled my position here. Lucky to load up on this gem. Foresee exciting short-term and long-term potential here. Recent pull back allows for tremendous investment here. Lots of shots on goal and appears to be a winner. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $PFE $GILD $LLY
0 · Reply
WickMaster
WickMaster Jun. 20 at 3:58 PM
$GILD
0 · Reply
MomentumWins
MomentumWins Jun. 20 at 3:51 PM
$GILD positive media coverage just now
0 · Reply
B5BusinessMan
B5BusinessMan Jun. 20 at 3:50 PM
$GILD sold it with -4 loss, sad day for me... 🫠
0 · Reply
ripztrip
ripztrip Jun. 20 at 3:32 PM
$CAPR shorts here are SO devious!!!! jeez. TRYING to do whatever they can to keep it BELOW 10?? this going to be approved shortly. marked. KNOW what you own!!!! This way a hit and run today with a lot of people with stop losses pushed out for no reason..... $SRPT $PFE $ABBV $GILD
0 · Reply
MidnightMadness
MidnightMadness Jun. 20 at 3:30 PM
$GILD Limited bottom line impact....may be correct as they balance pill/injection. The upside is protection of their market so they can build new product base to support growth. Oncology franchise has been slow to yield major benefit to shareholders....but fine wine takes time.
0 · Reply
MomentumWins
MomentumWins Jun. 20 at 3:27 PM
$GILD this was 119 just few weeks back. more upgrades will come Monday!!
0 · Reply
DonCorleone77
DonCorleone77 Jun. 20 at 2:41 PM
$GILD Information regarding Oppenheimer analyst report on GILD issued yesterday: https://x.com/CorleoneDon77/status/1936068317120221253
0 · Reply
ben_jamin03
ben_jamin03 Jun. 20 at 2:01 PM
$GILD and it drips what else is new
0 · Reply
FearlessRabbit
FearlessRabbit Jun. 20 at 1:36 PM
$GILD .
0 · Reply
FearlessRabbit
FearlessRabbit Jun. 20 at 1:20 PM
$GILD .
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 20 at 12:55 PM
$GILD $UNH Any and all Price critics are imbeciles. 14k a jab every six months vs what Pills cost up to 4,500 PER MONTH. Thats over $45,000 a year vs just 28k. With horrible side effects like long term liver damage, nausea etc, insurers/govt's will gladly switch to and pay for this all day every day at just 28K per year. And save billions in other liver side effects from pills, and pills expenditure and Gileads savings on raw materials for daily pills per person vs just two jabs a person? GILEAD WILL BE RICH.
0 · Reply
MomentumWins
MomentumWins Jun. 20 at 12:51 PM
$NBI $PPP $GILD
0 · Reply
MomentumWins
MomentumWins Jun. 20 at 12:49 PM
$NVDA This closed above 145, Final Trades recommendation, Sovereign AI, 200$ PT big break out ahead! Futures green!! $GILD
0 · Reply
Just2Cool
Just2Cool Jun. 20 at 12:40 PM
$GILD great news ! Why barely moved ?
0 · Reply
MomentumWins
MomentumWins Jun. 20 at 12:34 PM
$SPY $QQQ $BIIB $GILD https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/Wolfe-Research-Adjusts-Price-Target-on-Gilead-Sciences-to-135-From-115-50293228/ Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115 | MarketScreener
0 · Reply
MomentumWins
MomentumWins Jun. 20 at 12:26 PM
$GILD. HIV Game changing HIV injection affordable even in Africa might eradicate HIV in 20 years!! This injection also prevents spreading. $SPY $QQQ $PPP
0 · Reply